ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor

* Appointments support ProQR’s strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipeline * AX-0811, the first ProQR program identified through its AI-enabled discovered engine in clinical testing, with target engagement data expected in early January 2027 * ProQR’s expanded AI strategy is directly supporting the ongoing development programs; the Company expects up to 5 clinical data readouts over the next 12 months across 4 development programs LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced the appointments of: * Chris Hart, PhD, Chief Data and AI Officer – Dr. Hart most recently served as Vice President of Data Science and AI/ML at Eli Lilly and Company. * Thomas Wolf, PhD, Board of Directors as strategic AI advisor – Dr. Wolf is co-founder and Chief Science Officer of Hugging Face, which Nvidia has recently agreed to acquire. “I am thrilled to welcome Chris to ProQR’s management team and Thomas to the Board of Directors as strategic advisor. Together, they bring complementary and highly relevant expertise that will help us further integrate AI into drug discovery and development as we work to deliver more and better medicines to patients faster,” said Daniel A. de Boer, Chief Executive Officer of ProQR. “Chris brings more than 15 years of experience applying AI and machine learning to oligonucleotide therapeutics, most recently at Eli Lilly, while Thomas brings frontier AI experience from co-founding and building Hugging Face, a leading open-source AI platform. Their expertise comes at an important time for our RNA editing pipeline, with AX-0811, our first program identified through ProQR’s AI-enabled discovery process to enter clinical development, and the second, AX-2911, expected to follow in the coming months.”